



Abgenix to Present at JP Morgan 23rd Annual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Jan. 7, 2005--Abgenix, Inc. (Nasdaq: ABGX) today announced that the company will present at the JP Morgan 23rd Annual Healthcare Conference in San Francisco on Thursday, January 13, 2005 at 10:30 a.m. PT, 1:30 p.m. ET. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com. A replay of the webcast will also be available on the company's website until Thursday, January 27, 2005.

Bill Ringo, president and chief executive officer of Abgenix, will provide a company update and outlook for 2005.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

Statements made in this press release about Abgenix's technologies, product development activities, including clinical trials and clinical trials results, collaborative arrangements, process sciences and manufacturing activities, other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, product manufacturing, regulatory approval processes and meeting requirements for regulatory approval, competitive products and services, capital requirements and the extent and breadth of Abgenix's patent portfolio and other factors set forth in Abgenix's public filings with the Securities and Exchange Commission, including the risks described in Abgenix's quarterly report on Form 10-Q for the quarter ended September 30, 2004 and annual report on Form 10-K for the year ended December 31, 2003.

CONTACT: Abgenix, Inc.
Ami Knoefler, 510-284-6350 or 510-284-6605
(Senior Director, Corporate Communications and IR)

SOURCE: Abgenix, Inc.